Aktis Oncology, Inc. (AKTS) vs Apnimed, Inc. (APMD)

A side-by-side comparison of Aktis Oncology, Inc. and Apnimed, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

AKTS

Aktis Oncology, Inc.

$989M

$18.52HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

APMD

Apnimed, Inc.

$866M

$21.75HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — AKTS vs APMD

growth of $100 · dividends reinvested · last 1y

AKTS -17.3% (-17.3%/yr)APMD +35.9% (+35.9%/yr)APMD compounded faster over this window

AKTS APMD

Metrics side by side

APMD is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full AKTS analysis Full APMD analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.